Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma

Mateos, MV; Dimopoulos, MA; Cavo, M; Suzuki, K; Jakubowiak, A; Knop, S; Doyen, C; Lucio, P; Nagy, Z; Kaplan, P; Pour, L; Cook, M; Grosicki, S; Crepaldi, A; Liberati, AM; Campbell, P; Shelekhova, T; Yoon, SS; Iosava, G; Fujisaki, T; Garg, M; Chiu, C; Wang, J; Carson, R; Crist, W; Deraedt, W; Nguyen, H; Qi, M; San-Miguel, J

Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma

journal contribution

posted on 2023-02-21, 03:53 authored by MV Mateos, MA Dimopoulos, M Cavo, K Suzuki, A Jakubowiak, S Knop, C Doyen, P Lucio, Z Nagy, P Kaplan, L Pour, M Cook, S Grosicki, A Crepaldi, AM Liberati, P Campbell, T Shelekhova, SS Yoon, G Iosava, T Fujisaki, M Garg, C Chiu, J Wang, R Carson, W Crist, W Deraedt, H Nguyen, M Qi, J San-Miguel

Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma

History

Journal

New England Journal of Medicine

Volume

378

Pagination

518-528

Location

United States

Publisher DOI

https://doi.org/10.1056/NEJMoa1714678

ISSN

0028-4793

eISSN

1533-4406

Language

en

Author URL

https://www.ncbi.nlm.nih.gov/pubmed/29231133

Publication classification

C1.1 Refereed article in a scholarly journal

Issue

6

Publisher

Massachusetts Medical Society

Publication URL

http://dx.doi.org/10.1056/nejmoa1714678

Usage metrics

Keywords

Adult Aged Antibodies, Monoclonal Antineoplastic Combined Chemotherapy Protocols Bortezomib Disease-Free Survival Female Follow-Up Studies Humans Infections Intention to Treat Analysis Kaplan-Meier Estimate Male Melphalan Middle Aged Multiple Myeloma Prednisone Survival Rate

Licence

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma

History

Journal

Volume

Pagination

Location

Publisher DOI

ISSN

eISSN

Language

Author URL

Publication classification

Issue

Publisher

Publication URL

Usage metrics

Categories

Keywords

Licence

Exports